Swedish biotech firm gets green light to take diabetes candidate to clinical phase

Atrogi is starting clinical studies of its type 2 diabetes candidate, ATR-258, in Germany.

Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR

Atrogi, a biotech firm based in Sweden, is entering the clinical phase with its new class of molecules for the treatment of type 2 diabetes.

The company has just received authorization to start trials in humans, the company reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs